BiomX (NYSEMKT:PHGE) Stock Price Up 154.4% – Should You Buy?

BiomX Inc. (NYSEMKT:PHGE) shot up 154.4% during trading on Tuesday . The stock traded as high as $0.7762 and last traded at $1.88. 53,300 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 347,190 shares. The stock had previously closed at $0.7390.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating on shares of BiomX in a research note on Tuesday, November 25th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $399.00.

BiomX Stock Performance

The stock has a 50-day moving average price of $5.41 and a 200 day moving average price of $7.99. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $2.87 million, a price-to-earnings ratio of -2.51 and a beta of 1.56.

Institutional Investors Weigh In On BiomX

A number of hedge funds and other institutional investors have recently modified their holdings of PHGE. Nantahala Capital Management LLC boosted its holdings in BiomX by 44.1% in the first quarter. Nantahala Capital Management LLC now owns 2,493,309 shares of the company’s stock valued at $1,386,000 after purchasing an additional 762,709 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of BiomX during the first quarter worth approximately $166,000. Alyeska Investment Group L.P. lifted its holdings in shares of BiomX by 83.8% during the first quarter. Alyeska Investment Group L.P. now owns 1,590,738 shares of the company’s stock worth $884,000 after purchasing an additional 725,338 shares during the period. Allostery Investments LP increased its position in BiomX by 46.1% during the 1st quarter. Allostery Investments LP now owns 940,629 shares of the company’s stock worth $523,000 after purchasing an additional 296,796 shares during the period. Finally, Citadel Advisors LLC purchased a new position in shares of BiomX in the 3rd quarter valued at about $85,000. 40.57% of the stock is currently owned by institutional investors and hedge funds.

About BiomX

BiomX Ltd. is a clinical-stage biotechnology company developing targeted bacteriophage therapies designed to modulate the human microbiome. The company’s proprietary platform combines computational analytics with phage biology to identify and engineer virus-based agents that selectively target disease-associated bacteria without disrupting beneficial microbial communities. Through this precision approach, BiomX aims to address unmet needs in gastrointestinal and dermatological disorders driven by microbial dysbiosis.

BiomX’s pipeline includes investigational products for conditions such as Crohn’s disease, ulcerative colitis and acne.